KMT2Ar

2 clinical trials · Condition

Record	Firm	Date
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT06001788)	Kura Oncology, Inc.	2024-02-22
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML (NCT05735184)	Kura Oncology, Inc.	2023-07-18

Every clearance here is in the API, with alerts when new ones post.